JP2022500479A5 - - Google Patents
Info
- Publication number
- JP2022500479A5 JP2022500479A5 JP2021516638A JP2021516638A JP2022500479A5 JP 2022500479 A5 JP2022500479 A5 JP 2022500479A5 JP 2021516638 A JP2021516638 A JP 2021516638A JP 2021516638 A JP2021516638 A JP 2021516638A JP 2022500479 A5 JP2022500479 A5 JP 2022500479A5
- Authority
- JP
- Japan
- Prior art keywords
- sra141
- day
- cancer
- compound
- use according
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735778P | 2018-09-24 | 2018-09-24 | |
| US62/735,778 | 2018-09-24 | ||
| US201862760638P | 2018-11-13 | 2018-11-13 | |
| US62/760,638 | 2018-11-13 | ||
| USPCT/US2019/019676 | 2019-02-26 | ||
| PCT/US2019/019676 WO2019165473A1 (en) | 2018-02-26 | 2019-02-26 | Methods of treatment of cancer comprising cdc7 inhibitors |
| PCT/US2019/048657 WO2020068347A1 (en) | 2018-09-24 | 2019-08-28 | Methods of treatment of cancer comprising cdc7 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500479A JP2022500479A (ja) | 2022-01-04 |
| JPWO2020068347A5 JPWO2020068347A5 (https=) | 2022-09-02 |
| JP2022500479A5 true JP2022500479A5 (https=) | 2022-09-02 |
| JP7579781B2 JP7579781B2 (ja) | 2024-11-08 |
Family
ID=69952463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516638A Active JP7579781B2 (ja) | 2018-09-24 | 2019-08-28 | Ｃｄｃ７阻害剤を含む癌の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12533353B2 (https=) |
| EP (1) | EP3856352A4 (https=) |
| JP (1) | JP7579781B2 (https=) |
| KR (1) | KR20210064252A (https=) |
| CN (2) | CN121081469A (https=) |
| AU (1) | AU2019350581B2 (https=) |
| CA (1) | CA3113621A1 (https=) |
| WO (1) | WO2020068347A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3856352A4 (en) | 2018-09-24 | 2022-06-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising cdc7 inhibitors |
| BR112022000734A2 (pt) * | 2019-07-19 | 2022-04-12 | Takeda Pharmaceuticals Co | Método para tratar câncer em um paciente, uso de composto 1, e, composto 1 |
| BR112022001690A2 (pt) * | 2019-07-31 | 2022-05-03 | Oncour Pharma Inc | Tratamento de tumores imunes evasivos |
| JP2023535162A (ja) * | 2020-07-15 | 2023-08-16 | ユニヴェルシテ リーブル ド ブリュッセル | 抗新生物薬に対する感受性を決定するための方法 |
| CN121925259A (zh) * | 2023-09-27 | 2026-04-24 | 卡尔那生物科学株式会社 | 血液癌的新型联合疗法 |
| CN117563005A (zh) * | 2023-10-26 | 2024-02-20 | 浙江大学 | 一种治疗结直肠癌的药物组合物及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| BRPI0413438A (pt) | 2003-08-08 | 2006-10-17 | Pharmacia Italia Spa | derivados de pirimidilpirrol ativos como inibidores de cinase |
| US7371862B2 (en) | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| ZA200808966B (en) | 2006-03-27 | 2010-03-31 | Nerviano Medical Sciences Srl | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
| RU2008145225A (ru) | 2006-04-19 | 2010-05-27 | Новартис АГ (CH) | Соединения индазола и способы ингибирования cd7 |
| FR2907120B1 (fr) | 2006-10-12 | 2013-01-11 | Sanofi Aventis | Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7 |
| EP2118102B1 (en) | 2006-11-28 | 2013-06-12 | Nerviano Medical Sciences S.r.l. | Tricyclic indoles and (4,5-dihydro) indoles |
| EP2114157B1 (en) * | 2006-12-26 | 2021-05-26 | ImmunoGenesis, Inc. | Phosphoramidate alkylator prodrug for the treatment of cancer |
| WO2008104475A1 (en) | 2007-02-27 | 2008-09-04 | Nerviano Medical Sciences S.R.L. | Isoquinolinopyrrolopyridinones active as kinase inhibitors |
| TW200930375A (en) | 2007-12-21 | 2009-07-16 | Exelixis Inc | Benzofuropyrimidinones |
| EP2403857B1 (en) | 2009-03-05 | 2013-12-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
| KR20120024619A (ko) | 2009-04-20 | 2012-03-14 | 에스비아이 바이오테크 가부시키가이샤 | 티아졸리디논 유도체 |
| CA2767091A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
| CA2767089A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| CA2779843A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| TW201127384A (en) | 2009-11-18 | 2011-08-16 | Nerviano Medical Sciences Srl | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent |
| NZ602089A (en) | 2010-02-17 | 2014-05-30 | Takeda Pharmaceutical | Heterocyclic compounds having cell division cycle 7 inhibitory activity |
| WO2011112635A1 (en) | 2010-03-08 | 2011-09-15 | Sloan-Kettering Institute For Cancer Research | Cdc7 kinase inhibitors and uses thereof |
| MX2012012052A (es) | 2010-04-16 | 2013-03-21 | Abbvie Inc | Inhibidores de ftalazin-(2h)-ona de cinasas. |
| EP2558469B1 (en) | 2010-04-16 | 2014-08-13 | Abbvie Inc. | Pyrrolopyrazinone inhibitors of kinases |
| CA2795422A1 (en) | 2010-04-19 | 2011-10-27 | Abbvie Inc. | Pyrrolopyridine inhibitors of kinases |
| WO2012002568A1 (en) | 2010-06-29 | 2012-01-05 | Sbi Biotech Co., Ltd. | Azaindole derivative |
| DK2692728T3 (en) * | 2011-03-31 | 2018-10-08 | Carna Biosciences Inc | UNKNOWN FURANONDERIVATE |
| JP6569908B2 (ja) * | 2014-01-31 | 2019-09-04 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| US20200055848A1 (en) | 2016-11-04 | 2020-02-20 | Carna Biosciences, Inc. | Furanone derivates and methods of use thereof |
| WO2019165473A1 (en) * | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc | Methods of treatment of cancer comprising cdc7 inhibitors |
| EP3856352A4 (en) | 2018-09-24 | 2022-06-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising cdc7 inhibitors |
-
2019
- 2019-08-28 EP EP19866944.2A patent/EP3856352A4/en active Pending
- 2019-08-28 CN CN202511057693.2A patent/CN121081469A/zh active Pending
- 2019-08-28 WO PCT/US2019/048657 patent/WO2020068347A1/en not_active Ceased
- 2019-08-28 AU AU2019350581A patent/AU2019350581B2/en active Active
- 2019-08-28 US US17/275,732 patent/US12533353B2/en active Active
- 2019-08-28 CA CA3113621A patent/CA3113621A1/en active Pending
- 2019-08-28 CN CN201980069832.XA patent/CN113348020A/zh active Pending
- 2019-08-28 KR KR1020217010445A patent/KR20210064252A/ko not_active Ceased
- 2019-08-28 JP JP2021516638A patent/JP7579781B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500479A5 (https=) | ||
| US20230398119A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| EP2799070A1 (en) | Effect potentiator for antitumor agents | |
| JP2021525768A5 (https=) | ||
| JP2017526698A5 (https=) | ||
| Bennouna et al. | Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study | |
| Younes et al. | Novel agents in the treatment of Hodgkin lymphoma: biological basis and clinical results | |
| WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| JP2023024618A (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| WO2021063332A1 (zh) | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 | |
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| Ali et al. | Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers | |
| JP2016520665A (ja) | Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ | |
| CN111867678B (zh) | 治疗黑色素瘤的方法 | |
| JPWO2020068347A5 (https=) | ||
| JP2023505687A (ja) | 癌の処置方法 | |
| CN105611934A (zh) | 用于治疗化学敏感性或化学耐药性肿瘤的Dendrogenin A和抗肿瘤剂 | |
| WO2020239051A1 (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| Xu | Progress in Therapy of Lung Cancer | |
| CA3135916A1 (en) | Combined use of a-nor-5a androstane compound drug and anticancer drug | |
| CN115243719A (zh) | CTB006与Ponatinib联合应用 | |
| CN106333951B (zh) | 一种mTOR激酶抑制剂与MAPK激酶抑制剂的组合物的应用 | |
| JPWO2021108682A5 (https=) | ||
| CN107137403B (zh) | 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途 |